webinar register page

Topic

The clinical use of antivirals for influenza

Description

A webinar for healthcare professionals, researchers and clinicians. In this, our third topic of the APACI Antiviral series, experts will discuss the use of antiviral therapies for influenza in the Asia Pacific region, when to use them and the role they play. They will also discuss how this translates to the current COVID-19 Pandemic. This engaging webinar will allow you to have your questions answered on the clinical significance of antiviral medications.

At the end of this webinar, participants will be able to:

a) Summarise the use of antivirals and associated diagnostics - when
to use them and the role they play
b) Identify the early treatment to reduce spread during a pandemic
i. In influenza
ii. How it translates into the COVID pandemic
c) Describe antiviral resistance
i. Frequency of resistance
ii. Impact on patient
iii. Risk of transmission
d) Describe REMAP-CAP and the lessons from COVID to improve
influenza therapeutics.

Time

Dec 8, 2020 07:30 PM in Hong Kong SAR

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Suzi Blackburn.

All fields are required

Your Information
Send to
Message preview	Hi there, You are invited to a Zoom webinar. When: Dec 8, 2020 07:30 PM Hong Kong SAR Topic: The clinical use of antivirals for influenza Register in advance for this webinar: https://us02web.zoom.us/webinar/register/WN_rJaVhvHFTvScDij_5-MMNg After registering, you will receive a confirmation email containing information about joining the webinar. ---------- Webinar Speakers Dr Emi Takashita (Senior Research Scientist @National Institute of Infectious Diseases) Emi Takashita is a Technical Official at the Ministry of Health, Labour and Welfare, Japan and a Senior Research Scientist at the National Institute of Infectious Diseases (NIID), Japan. She specialized in influenza viruses as a Postdoctoral Fellow at the Department of Infectious Diseases, Yamagata University Faculty of Medicine, Japan and then became an Assistant Professor. She joined the Influenza Virus Research Center at the NIID, one of the WHO Collaborating Centres for Reference and Research on Influenza, in 2009, and has been leading the Antiviral Resistance Surveillance Team. Her team monitors the susceptibility of influenza viruses to NA inhibitors, M2 inhibitors and RNA polymerase inhibitors. She is a member of the WHO GISRS Expert Working Group for Surveillance of Antiviral Susceptibility (WHO-AVWG) and an external expert of the Pharmaceuticals and Medical Devices Agency (PMDA), which is the Japanese regulatory agency. Prof Steve Webb (Deputy Chair @Australian Clinical Trials Alliance) Dr Steve Webb is an ICU specialist at Royal Perth Hospital, a Professor of Critical Care Research at Monash University, and Deputy Chair of the Australian Clinical Trials Alliance. He designs and conducts clinical trials that generate evidence to improve patient care. He is named as an investigator on more than $115 M in research funding, has been an investigator on trials with an accumulated sample size of more than 50,000 patients, and has published more than 180 manuscripts including in the NEJM (6), JAMA (5), and The Lancet (2). He has particular experience with Bayesian adaptive platform trials and other innovative designs such as cluster cross-over trials. Prof David Smith (Medical Virologist ) Clinical Professor David Smith is a Medical Virologist at PathWest Laboratory Medicine WA and Director of the PathWest QE2 Network. He is also a Clinical Professor in the School of Pathology and Laboratory Medicine at the University of Western Australia, and Director of the National Influenza Centre at PathWest. He chairs the Public Health Laboratory Network and is a Director of the Asia-Pacific Alliance for the Control of Influenza. He has a particular interest in influenza and other respiratory viruses, mosquito-borne viruses and emerging infections.

Time Zone:

webinar register page

Share via Email

Switch Time Zone

Upcoming Meetings